Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and SART in Oligometastatic Melanoma
NCT01565837Phase 2Unknown
- Start
- Aug 2012
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma. Status: unknown.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01565837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565837.